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Abstract
AIMS: To evaluate the antitumor and antiangiogenic activity of metronomic ceramide analogs and their relevant
molecular mechanisms. METHODS: Human endothelial cells [human dermal microvascular endothelial cells and
human umbilical vascular endothelial cell (HUVEC)] and pancreatic cancer cells (Capan-1 and MIA PaCa-2) were
treated with the ceramide analogs (C2, AL6, C6, and C8), at low concentrations for 144 hours to evaluate any
antiproliferative and proapoptotic effects and inhibition of migration and to measure the expression of caveolin-1
(CAV-1) and thrombospondin-1 (TSP-1) mRNAs by real-time reverse transcription–polymerase chain reaction.
Assessment of extracellular signal–regulated kinases 1 and 2 (ERK1/2) and Akt phosphorylation and of CAV-1
and cyclin D1 protein expression was performed by ELISA. Maximum tolerated dose (MTD) gemcitabine was com-
pared against metronomic doses of the ceramide analogs by evaluating the inhibition of MIA PaCa-2 subcutaneous
tumor growth in nude mice. RESULTS: Metronomic ceramide analogs preferentially inhibited cell proliferation and
enhanced apoptosis in endothelial cells. Low concentrations of AL6 and C2 caused a significant inhibition of HUVEC
migration. ERK1/2 and Akt phosphorylation were significantly decreased after metronomic ceramide analog treat-
ment. Such treatment caused the overexpression of CAV-1 and TSP-1 mRNAs and proteins in endothelial cells,
whereas cyclin D1 protein levels were reduced. The antiangiogenic and antitumor impact in vivo of metronomic
C2 and AL6 regimens was similar to that caused by MTD gemcitabine. CONCLUSIONS: Metronomic C2 and AL6
analogs have antitumor and antiangiogenic activity, determining the up-regulation of CAV-1 and TSP-1 and the
suppression of cyclin D1.
Neoplasia (2012) 14, 833–845
Abbreviations: CAV-1, caveolin-1; EGF, epidermal growth factor; ERK, extracellular signal–regulated kinase; HMVEC-d, human dermal microvascular endothelial cells; HU-
VEC, human umbilical vascular endothelial cell; MC, metronomic chemotherapy; MTD, maximum tolerated dose; TSP-1, thrombospondin-1; VEGF, vascular endothelial
growth factor
Address all correspondence to: Guido Bocci, MD, PhD, Division of Pharmacology, Department of Internal Medicine, University of Pisa, Via Roma, 55, I-56126 Pisa, Italy.
E-mail: guido.bocci@med.unipi.it
1The study has been funded, in part, by the Italian Association for Cancer Research (AIRC).
2This article refers to supplementary material, which is designated by Figure W1 and is available online at www.neoplasia.com.
3These authors contributed equally to this work.
Received 5 May 2012; Revised 30 July 2012; Accepted 30 July 2012
Copyright © 2012 Neoplasia Press, Inc. All rights reserved 1522-8002/12/$25.00
DOI 10.1593/neo.12772
www.neoplasia.com
Volume 14 Number 9 September 2012 pp. 833–845 833
Introduction
Pancreatic cancer is the fourth leading cause of cancer-related deaths
in the United States and in Europe [1]. Current therapy for pancre-
atic cancer involves surgery and chemotherapy, but metastatic disease
is resistant to most cytotoxic chemotherapeutic agents and to novel
targeted therapies [2]. Gemcitabine is the main chemotherapeutic
agent used to treat advanced adenocarcinoma of the pancreas (even
though it does not prolong significantly the survival of patients), and
more effective therapeutic options are urgently needed to improve
the response and the survival of patients with this cancer. Among
the emerging therapeutic approaches, metronomic chemotherapy
(MC), the continuous administration of low-dose chemotherapeutic
drugs, is one interesting option because of its good tolerability and
the low costs associated with palliative treatments [3–5]. Such a reg-
imen has been shown to have antiangiogenic activity and to inhibit
tumor growth in vivo [6–8]. Moreover, the immunomodulating ac-
tivity of low-dose cyclophosphamide seems to contribute to the anti-
tumor effect of MC on established rat lymphomas and sarcomas [9].
Furthermore, metronomic paclitaxel preclinically enhanced the anti-
tumor effects of cancer vaccine by depleting regulatory T lymphocytes
and inhibiting tumor angiogenesis [10]. Clinically, metronomic low-
dose cyclophosphamide induced stable tumor-specific T-cell responses,
which correlated with improved clinical outcome in advanced-stage
breast cancer patients [11]. In the clinic, the benefits of MC have
been demonstrated in a number of phase II clinical trials with a
broad range of malignancies at advanced stages [12–14]. Interest-
ingly, very few preclinical and clinical data are available on MC for pan-
creas cancer, and almost all such studies only evaluated metronomic
gemcitabine [15–17].
Ceramide, a sphingosine-based lipid molecule, has attracted con-
siderable interest for tumor treatment because of its emerging role as
an intracellular proapoptotic molecule [18]. Ceramides are second
messengers that play an important role in regulating cell growth, dif-
ferentiation, and the cell death program [19,20]. Furthermore, the
dynamic balance between the levels of ceramide and sphingosine-
1–phosphate is an important factor that determines whether a cell
survives and proliferates or whether it dies [21]. Ceramide induces
proapoptotic mechanisms by activating ceramide-activated phospha-
tases and ceramide-activated kinases and by regulating protein kinase C
(PKC), Akt, and Bcl-2 [22–24]. Indeed, tumor cells with low levels of
endogenous ceramides are resistant to apoptosis, and tumor cell lines
with a defect in ceramide generation are resistant to radiation-induced
apoptosis [25]. Moreover, the glycosylation of ceramide, through the
glucosylceramide synthase enzyme, confers resistance to doxorubicin
in human breast cancer cells [26,27] and potentiates cellular multidrug
resistance [28,29].
Endogenous ceramides are unable to cross the cell membrane, and
therefore, they cannot be used as anticancer agents. Ceramide analogs,
however, are able to pass through the cell membrane and to mimic the
effects of endogenous ceramide. Such analogs have been developed in
the past; in particular, C2 and C6 ceramide analogs have been inves-
tigated over the years as new potential drugs for cancer chemotherapy
[30]. C2 and C6 ceramide analogs induce apoptosis in leukemic cell
lines [31,32], and moreover, they proved to mimic ceramide by in-
ducing apoptosis and by inhibiting proliferation of tumor cells but
at concentrations that were considered to be too high for their devel-
opment as potential antiproliferative agents [33]. Other promising
ceramide analogs, such as the AL6 compound, which has a wide spec-
trum of cellular activities, have recently been synthesized [34], and
furthermore, AL6 has also been successfully tested on pancreatic
tumor cells [35].
In the present study, we tested the hypothesis that metronomic
ceramide analogs can have an impact on the proliferation and on
apoptosis of endothelial cells and that they can also inhibit tumor
growth and tumor angiogenesis. To the best of our knowledge, this
is the first time that such a hypothesis has been tested. We also pre-
sent the results of our investigation into the possible mechanisms
by which ceramide analog treatments can inhibit tumor growth.
Materials and Methods
Materials, Drugs, and Cell Lines
Recombinant human vascular endothelial growth factor (rhVEGF)
and recombinant human epidermal growth factor (rhEGF) were
from PeproTech EC Ltd. (London, United Kingdom). Cell culture
media MCDB13, Dulbecco’s modified Eagle’s medium, and RPMI,
FBS, horse serum, L-glutamine, penicillin, streptomycin, and genta-
micin were purchased from Gibco (Gauthersburg, MD). Type A
gelatin from porcine skin, supplements, and all other chemicals
not listed in this section were obtained from Sigma Chemical Co.
(St Louis, MO). Sterile plastics for cell culture were purchased from
Costar (Cambridge, MA).
AL6 ceramide analog was a generous gift from Bracco S.p.A.
(Milan, Italy), and C2, C6, and C8 ceramide analogs were purchased
from Calbiochem (Darmstadt, Germany). The chemical structures of
these compounds are shown in Figure 1. The compounds were dis-
solved to form a stock solution of 10 mM in 50% DMSO and 50%
ethanol for in vitro and in vivo studies. Gemcitabine (Ely Lilly and
Company, Indianapolis, IN) for in vivo studies was purchased from
the hospital pharmacy. Human dermal microvascular endothelial
cells (HMVEC-d) were obtained from Clonetics (San Diego, CA);
human umbilical vascular endothelial cells (HUVECs) were obtained
from the American Type Culture Collection (Manassas, VA). Endo-
thelial cells were maintained in MCDB131 culture medium supple-
mented with 10% heat-inactivated FBS, L-glutamine (2 mM),
heparin (10 U/ml), EGF (10 ng/ml), and basic fibroblast growth fac-
tor (5 ng/ml). The human pancreatic tumor cell lines MIA PaCa-2
and Capan-1 were purchased from the American Type Culture Col-
lection and maintained in 10% FBS–Dulbecco’s modified Eagle’s
medium and RPMI medium, respectively. Media were supplemented
with L-glutamine (2 mM). HUVEC, HMVEC-d, MIA PaCa-2, and
Capan-1 cells were routinely grown in 75-cm2 tissue culture flasks
and kept in a humidified atmosphere of 5% CO2 at 37°C. Cells
were harvested when they were in a log phase of growth, using a
solution of 0.25% trypsin–0.03% EDTA, and thereafter, they were
maintained at the above-described cell culture conditions for all
subsequent experiments.
In Vitro Studies
Cell proliferation assay and apoptosis measurements. Endothelial
(HUVEC and HMVEC-d; 1 × 103 cells/well) and tumor (MIA
PaCa-2 and Capan-1; 0.5 × 103 cells/well) cells were plated onto
24-well sterile plastic plates (1% gelatin coated for the endothelial
cells) and allowed to attach overnight. Cells were treated with cera-
mide analogs C2, AL6, C6, and C8 (0.001–100 nM) or with vehicle
alone continuously for 144 hours in 1 ml of medium. For all samples,
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the media were changed every 24 hours [8]. At the end of the treat-
ment, viable cells were quantified using an ADAM-MC cell counter
(Digital Bio, NanoEnTek Inc., Seoul, South Korea). The data are pre-
sented as the percentage of the vehicle-treated cells. The concentra-
tion of drug that reduced cell proliferation by 50% (IC50) versus
controls was calculated by nonlinear regression fit of the mean values
of the data obtained in triplicate experiments (at least nine wells for
each concentration).
To quantify the degree of apoptosis induced by the drug treat-
ments, HMVEC-d, HUVEC, MIA PaCa-2, and Capan-1 cells were
treated continuously for 144 hours with ceramide analogs (C2, AL6,
C6, and C8) at a concentration corresponding to the experimental
IC50, or at a lower concentration, or with vehicle alone. At the end
of the experiment, cells were collected and the Cell Death Detection
ELISA Plus Kit (Roche, Basel, Switzerland) was used as per the man-
ufacturer’s instruction. The OD was determined using a Multiskan
Spectrum microplate reader (Thermo Labsystems, Milan, Italy) set
to 405 nm (with a wavelength correction set to 490 nm). All ex-
periments were repeated three times with at least three replicates
per sample.
Migration assay. Migration assays were performed as previously
described [36]. Briefly, viable HUVEC and MIA PaCa-2 cells
were seeded at a density of 8.4 × 104 cells in 500 μl of serum-free
MCDB131 in the upper chamber of 8-μm pore modified Boyden
chamber (Becton Dickinson, Franklin Lakes, NJ). Cells were treated
for 4 hours [36,37] with the ceramide analog C2 or AL6 at a con-
centration corresponding to the experimental 144-hour IC50 and at
100 pM in HUVEC or at 10 nM in MIA PaCa-2 cells to study only
the effects on the migration process without impairing the cell via-
bility. Vehicle alone was used as a control. Cells were allowed to mi-
grate in 250 μl of medium with or without added rhVEGF or rhEGF
(100 ng/ml) as a chemoattractant for endothelial and cancer cells,
respectively; after 4 hours, the membranes were fixed, stained with
hematoxylin, and then mounted onto slides. The pictures of the
migrated cells were acquired as 512 × 1024 pixel images at 400×
magnification using a digital microscope Axioplan2 (Carl Zeiss,
Oberkochen, Germany; see Figure W1) and processed by image
analysis software (ImageJ v.1.45s, National Institutes of Health,
Bethesda, MD). Twenty different regions were analyzed in each slide
to calculate the number of migrated cells, and the results are pre-
sented as a percentage of the controls. The experiments were per-
formed in triplicate.
Detection of Akt and extracellular signal–regulated kinases 1 and
2 phosphorylation, caveolin-1, and cyclin D1 levels in endothelial
and cancer cells by ELISA after metronomic ceramide analog
treatments. HUVEC and HMVEC-d (10 × 104 cells/well) and
MIA PaCa-2 and Capan-1 (5 × 104 cells/well) were treated contin-
uously for 144 hours with ceramide analogs (C2, AL6, C6, and C8)
at a concentration corresponding to the experimental IC50 of cell
proliferation and at a lower concentration. At the end of the drug
Figure 1. Effect of ceramide analogs (A) C2, (B) AL6, (C) C6, and (D) C8 on in vitro cell proliferation. The antiproliferative effects of each
drug was studied using continuous exposures (144 hours) to the drugs of HMVEC-d, HUVEC, Capan-1, and MIA PaCa-2 cells. Symbols
and bars, mean values ± SD, respectively. *P < .05 versus vehicle-treated controls.
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exposure, cells were harvested and immediately frozen in liquid
nitrogen. Cells were lysed as per manufacturer’s instructions. Each
sample was then assayed for human extracellular signal–regulated
kinases 1 and 2 (ERK1/2) and Akt phosphorylation by the Phospho-
Detect ERK1/2 (pThr185/pTyr187) ELISA Kit and the PhosphoDetect
Akt (pThr308) ELISA Kit (Calbiochem) and normalized by total pro-
tein ERK1/2 and Akt concentration, respectively. To measure the pro-
tein levels of human caveolin-1 (CAV-1) and human cyclin D1, we
used the CAV-1 ELISA Kit and the Cyclin D1 ELISA Kit (USCN Life
Science & Technology, Wuhan, China) and normalized by total
protein concentration. The OD was determined using the Multiskan
Spectrum microplate reader set to 450 nm. All the absorbance values
were plotted as a percentage of signal relative to that of control cells
(i.e., vehicle only). All experiments were repeated three times with a
least three replicates per sample.
Immunohistochemical analysis for CAV-1 in endothelial cells.
The procedure for immunohistochemistry was performed as previ-
ously described [38] on HUVECs treated with AL6 or with vehicle
alone. Endogenous peroxidase activity was blocked by incubating the
slides in 1% hydrogen peroxide and methanol for 10 minutes. After
blocking of nonspecific staining with normal serum, the slides were
incubated with primary antibody anti–CAV-1 rabbit polyclonal anti-
body (Chemicon International, Temecula, CA; 1:200 dilution), then
with biotinylated secondary antibody (1:500 dilution for 30 minutes)
and the avidin-biotin complex (Vector Laboratories, Burlingame, CA,
for 30 minutes). The 3,3′-diaminobenzidine tetrahydrocloride was
used as chromogen. Negative controls were obtained by omitting
the primary antibody.
Real-time reverse transcription–polymerase chain reaction analysis
of human CAV-1 and TSP-1 gene expression. To evaluate the
expression of CAV-1 and thrombospondin-1 (TSP-1) mRNAs, we grew
HUVEC and HMVEC-d (at 10 × 104 cells/well) and MIA PaCa-2 and
Capan-1 (at 5 × 104 cells/well) cells in their respective media and treated
them continuously for 144 hours with ceramide analogs (C2, AL6, C6,
and C8) at concentrations corresponding to the experimental IC50 for
cell proliferation, as well as at lower concentrations, or with vehicle
alone. Next, in brief, total RNA (1 μg) was reverse transcribed at 37°C
for 1 hour in a 100-μl reaction volume containing 0.8 mM deoxy-
nucleotide mix (deoxyribonucleotide triphosphates [dNTPs]), 200 U
of Moloney murine leukemia virus reverse transcriptase, 40 U of
RNase inhibitor, and 0.05 μg/ml random primers. The resulting
cDNA was diluted (2:3) and then amplified by quantitative reverse
transcription–polymerase chain reaction using the Applied Biosystems
7900HT sequence detection system (Applied Biosystems, Foster City,
CA). CAV-1 (Assay ID Hs00184697_m1) and TSP-1 (Assay
ID00170236_m1) were purchased from Applied Biosystems. The
PCR thermal cycling conditions and the optimization of primer con-
centrations were as per the manufacturer’s instructions. Amplifications
were normalized to glyceraldehyde-3-phosphate dehydrogenase, and
the quantitation of gene expression was performed using the ΔΔC t
calculation, where C t is the threshold cycle. The amount of target, nor-
malized to the endogenous control and relative to the calibrator (i.e.,
vehicle-treated control cells), was calculated using the formula 2−ΔΔC t.
Human TSP-1 detection in conditioned media by ELISA. HUVECs
andHMVEC-d were treated continuously for 144 hours with ceramide
analogs at a concentration corresponding to the experimental IC50 of
cell proliferation, as well as to lower concentrations of the drug, or with
vehicle alone. To measure the amount of secreted TSP-1 at the end of
the incubation, we discarded the medium of each well and replaced it
with serum-free medium for 4 hours, as previously described [39]. Each
sample was then assayed for TSP-1 protein using the ELISA Quanti-
kine Kit (R&D Systems, Minneapolis, MN) and normalized by total
protein concentration in each sample. The OD was determined using
the Multiskan Spectrum microplate reader set to 450 nm. All experi-
ments were independently repeated six times, with at least nine samples
for each tested drug concentration.
In Vivo Studies
Animals. CD nu/nu male mice, weighing 20 to 25 g, were sup-
plied by Charles River (Milan, Italy) and were allowed unrestricted
access to sterile food and water. Housing and all procedures involving
animals were performed according to the protocol approved by the
Academic Committee for Animal Experimentation of the University
of Pisa, in accordance with the European Community Council Direc-
tive 86-609, recognized by the Italian government, on animal welfare.
Each experiment employed the minimum number of mice needed to
obtain statistically meaningful results.
MIA PaCa-2 tumor xenografts in nu/nu mice and drug treat-
ments. MIA PaCa-2 cell viability was assessed by trypan blue
dye exclusion, and on day 0, a 1.3 × 106 ± 5% inoculum of cells/
mouse was implanted subcutaneously in a 0.2-ml volume of serum-
free media between the scapulae of each mouse. Animal weights were
monitored and, upon the appearance of a visible subcutaneous tumor
mass, tumor dimensions were measured every 2 days in two perpen-
dicular directions using calipers. Tumor volume (mm3) was defined
as follows: [(w1 × w1 × w2) × (π/6)], where w1 and w2 are the largest
and smallest tumor diameters (mm), respectively. The mice were
then randomized into groups of six animals. To treat established tu-
mors, we first allowed the xenografts to grow for 15 days. Thereafter,
gemcitabine, C2, and AL6 were administered as follows: 1) group 1,
gemcitabine given at the maximum tolerated dose (MTD; as a pos-
itive control)—two cycles of 120 mg/kg four times at 3-day inter-
vals [40]; 2) groups 2 and 3 were treated with either ceramide
analog C2 (group 2) or with AL6 (group 3) given everyday at a dose
of 0.5 mg/kg per day; 3) group 4 (control group) was injected intra-
peritoneally (i.p.) with vehicle alone [saline solution and 1.9%
DMSO and 1.9% ethanol (vol/vol)]. The experiment was terminated
57 days after the inoculation of the tumor cells. Mice were sacrificed
by an anesthetic overdose.
In a separate experiment, dosing began 16 days after cell inocula-
tion. Gemcitabine, C6, or C8 was then administered as follows: 1)
group 1, gemcitabine at the MTD; 2) groups 2 and 3 were treated
with ceramide analog C6 (group 2) or C8 (group 3) given everyday
at a dose of 0.5 mg/kg per day; 3) group 4 (control group) was in-
jected i.p. with vehicle alone [saline solution and 1.9% DMSO and
1.9% ethanol (vol/vol)]. Three groups were terminated on day 27
(groups 2, 3, and 4), and one group on day 35 (group 1) after tumor
cell implantation.
Immunohistochemistry of Ki67 and microvessel density on MIA
PaCa-2 tumor tissue samples. After surgical resection at the end
of the in vivo experiment, tumor tissue samples from all the different
treatment groups were fixed in 10% phosphate-buffered formalin
836 Metronomic Ceramide Analogs Bocci et al. Neoplasia Vol. 14, No. 9, 2012
for 12 to 24 hours and then embedded in paraffin for histology and
immunohistochemistry. Five-micrometer sections were stained with
hematoxylin-eosin for histologic analysis. Adjacent sections were cut
for immunohistochemistry as previously described [41] using the fol-
lowing primary antibodies: anti-Ki67 clone MIB-1 (1:50 dilution;
Zymed Laboratories Inc., South San Francisco, CA) as a cellular
marker for proliferation [42] and the rat anti-mouse CD31 (1:100
dilution; PharMingen, San Diego, CA) to evaluate microvascular
density. Negative controls were obtained by replacing the primary
antibody with nonimmune serum. Nuclear staining was considered
positive for MIB-1. The degree of positivity was evaluated by calcu-
lating the percentage of immunoreactive cells in a minimum count of
500 cells [43]. To calculate microvessel density, we selected the three
most vascularized areas of the tumor (“hot spots”) and obtained the
mean values by counting the vessels. A single microvessel was defined
as a discrete cluster of cells positive for CD31 staining, with no re-
quirement for the presence of a lumen. Microvessel counts were per-
formed at ×200 (×20 objective lens and ×10 ocular lens; 0.74 mm2
per field) [39]. All parameters were determined independently by
three expert pathologists (P.V., A.G.N., and G.F.), and discordant
cases were solved by simultaneous review.
Statistical Analysis
Analysis by analysis of variance followed by the Student-Newman-
Keuls test was used to assess the statistical differences in the in vitro
and in vivo data. P values lower than .05 were considered significant.
Statistical analyses were performed using the GraphPad Prism soft-
ware package version 5.0 (GraphPad Software Inc., San Diego, CA).
Results
In Vitro Studies
Metronomic ceramide analogs preferentially inhibit proliferation
and induce apoptosis in endothelial cells. The 144-hour exposure
to ceramide analogs (C2, AL6, C6, and C8) inhibited cell prolifera-
tion of HMVEC-d and HUVEC in a concentration-dependent man-
ner (Figure 1); the calculated IC50 values in HMVEC-d were 4.99 ±
3.60 nM for C2 (Figure 1A), 4.85 ± 3.14 nM for AL6 (Figure 1B),
28.95 ± 17.57 nM for C6 (Figure 1C ), and 3.56 ± 0.92 nM for C8
(Figure 1D). Analogously, in HUVECs, the IC50s were 6.21 ± 3.05 nM
for C2 (Figure 1A), 4.37 ± 1.30 nM for AL6 (Figure 1B), 23.54 ±
8.14 nM for C6 (Figure 1C), and 2.88 ± 0.91 nM for C8 (Figure 1D).
In contrast, the ceramide analogs did not significantly affect the prolif-
eration of MIA PaCa-2 and Capan-1 cell lines at these low concentra-
tions (Figure 1), with the observed IC50s being higher than 100 nM
(the only exception noted was for AL6 in Capan-1 cells, IC50 =
12.90 ± 8.56 nM, Figure 1B).
Apoptosis was significantly increased in both HMVEC-d
(Figure 2A) and HUVEC (Figure 2B). Interestingly, the increasing
concentrations of ceramide analogs (C2, AL6, C6, and C8) induced
smaller percentages of apoptotic cells in the endothelial cells
HMVEC-d (Figure 2A) and HUVEC [with the only exception of
C2 (5 nM and 100 pM); Figure 2B], whereas the proliferation was
a clearly concentration-dependent effect. These apoptotic effects
were not enhanced in the MIA Paca-2 cancer cell line (Figure 2C )
nor in the Capan-1 cell line (Figure 2D) after treatment with
ceramide analogs.
Figure 2. Proapoptotic effects of ceramide analogs C2, AL6, C6, and C8 on proliferating (A) HMVEC-d, (B) HUVEC, (C) MIA PaCa-2, and
(D) Capan-1 cells, after 144 hours of treatment. Columns and bars, mean values ± SD, respectively. *P < .05 versus vehicle-treated
controls. Control− stands for the negative control of the ELISA kit.
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Metronomic ceramide analogs AL6 and C2 inhibit cell migration
in endothelial and cancer cells. Figure 3A shows the significant
inhibition of VEGF-induced migration of HUVECs treated at low
concentrations of AL6 and C2 ceramide analogs. The chemoattractant
activity of VEGF on endothelial cells was significantly blocked by both
drugs tested, in particular by AL6 at 100 pM (Figure 3A), which
showed the greatest inhibition against HUVECs (24.33 ± 1.45% of
migrated cells vs 100% of controls; P < .05). Inhibition of EGF-
induced MIA PaCa-2 cancer cell migration was not significant at low
concentrations of AL6, although it was statistically different at higher
concentrations (i.e., 100 nM; 51 ± 2.08% of migrated cells vs 100% of
controls; P < .05; Figure 3B). C2 inhibited cancer cell migration at
higher concentrations and at a lower rate when compared to the effects
observed with the endothelial cells (Figure 3B).
Figure 3. Effects of low-dose treatment with ceramide analogs C2 and AL6 on (A) endothelial cell and (B) cancer cell migration. Columns
and bars, mean values ± SD, respectively. *P < .05 versus vehicle-treated controls.
Figure 4. Modulation of Akt (pThr308) and ERK1/2 (pThr185/pTyr187) phosphorylation by ceramide analogs C2, AL6, C6, and C8 in
(A) HMVEC-d, (B) HUVEC, (C) MIA PaCa-2, and (D) Capan-1 cells after 144 hours of treatment. pAkt and phosphorylated ERK1/2 con-
centrations were measured by ELISA and normalized to total Akt and ERK1/2 protein concentration, respectively. Columns and bars,
mean values ± SD, respectively. *P < .05 versus vehicle-treated controls.
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Phosphorylation of ERK1/2 and Akt is inhibited after exposure to
metronomic ceramide analogs. Figure 4A shows the strong inhi-
bition of ERK1/2 and Akt phosphorylation in HMVEC-d micro-
vascular endothelial cell line after metronomic exposure to ceramide
analogs. This inhibition is more evident for phosphorylated Akt
(pAkt) with all analogs tested but, in particular, in samples treated
with C2 and AL6. Differently, in HUVECs, the percentage of inhi-
bition of pAkt and phosphorylated ERK1/2 was superimposable
(Figure 4B). The decrease in phosphorylation of ERK1/2 and Akt was
also observed in the two cancer cell lines MIA PaCa-2 (Figure 4C) and
Capan-1 (Figure 4D), but these effects were seen at higher concen-
trations for all the compounds tested. However, the reduction in
phosphorylation in the samples treated with C2 and AL6 was less pro-
nounced than that observed in endothelial cells.
Metronomic ceramide analogs upregulate CAV-1 in endothelial
and cancer cells. To investigate the possible mechanisms underly-
ing the antiproliferative and proapoptotic effects of metronomic cer-
amide analogs, real-time PCR analysis and protein quantification
were performed to evaluate the expression of CAV-1. Interestingly,
up-regulation of CAV-1 (Figure 5) was found in both endothelial
and tumor cells after treatment with ceramide analogs. Indeed,
CAV-1 gene expression was significantly increased by AL6 treatment
in endothelial cells (Figure 5A) and in cancer cells (Figure 5B). To
verify that the increase of CAV-1 mRNA in treated cells resulted in
an actual increase in relative protein levels, we quantified CAV-1
by ELISA in the lysate of vehicle-treated and of drug-treated cells.
In HMVEC-d and HUVECs, there was a significant increase
of CAV-1 after 144-hour treatment with all four ceramide ana-
logs (Figure 5C ), with a particularly significant increase in the cells
treated with AL6 (5 nM). This up-regulation of CAV-1 protein was
also observed in the tumor cell lines (although to a different extent
in the MIA Paca-2 and Capan-1 cells at higher drug concentra-
tions, and such differences were not always statistically significant;
Figure 5D). In addition, we performed CAV-1 immunohistochem-
istry on vehicle-treated and on AL6-treated HUVECs. The histology
of HUVECs (Figure 6A) confirmed the typical morphology of endo-
thelial cells grown as monolayers (i.e., large-sized cells with evident
pseudopodia), whereas CAV-1 immunohistochemistry in vehicle-treated
cells revealed the staining to be at both cytoplasmic and membrane
levels (Figure 6B). A considerable increase in the amount of protein
was found in AL6-treated cells (Figure 6C) when compared with the
immunoreactivity of controls, confirming the increased level of expres-
sion observed by the reverse transcription–polymerase chain reaction
and ELISA methods.
Metronomic ceramide analogs decrease cyclin D1 in endothelial
and cancer cells. Intracellular levels of protein cyclin D1 were
found to be reduced in both endothelial cell lines after treatment
with metronomic ceramide analog compounds, an effect that was
found to be statistically significant. In particular, a 144-hour treat-
ment with C2 and AL6 caused a marked reduction of cyclin D1
levels (e.g., 28 ± 2% AL6 (5 nM) vs 100% of controls in HMVEC-d;
Figure 7A). This reduction was also found, although to a lesser
extent, in the two cancer cell lines, MIA PaCa-2 and Capan-1
(Figure 7B). Interestingly, AL6 (at 100 nM) caused a reduction of
Figure 5. CAV-1 gene expression in (A) endothelial and (B) pancreatic cancer cell lines exposed to AL6, or to vehicle alone, for 144 hours.
Gene expression was quantified by the formula 2−ΔΔC t. CAV-1 protein concentration in cell lysates after exposure to C2, AL6, C6, and C8 or
to vehicle alone for 144 hours in (C) endothelial and (D) pancreatic cancer cell lines. CAV-1 concentrationwasmeasuredwith an ELISA kit and
normalized to total protein concentration. Columns and bars, mean values ± SD, respectively. *P < .05 versus vehicle-treated controls.
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56 ± 12% and 68 ± 6% versus 100% of controls for MIA PaCa-2 and
Capan-1 cells, respectively.
TSP-1 mRNA and TSP-1 protein secretion are increased by
metronomic ceramide analogs. Real-time PCR analysis was per-
formed to evaluate the expression of TSP-1 in endothelial and cancer
cells. This analysis showed a significant increase in TSP-1 mRNA
expression in endothelial cells after treatment with AL6 (5 nM).
Thus, we observed this effect on both HMVEC-d (1.706 ± 0.07 vs
1 of controls) and HUVECs (1.583 ± 0.119 vs 1 of controls;
Figure 7C ). In MIA PaCa-2 and Capan-1 tumor cells, the expression
of TSP-1 was unaltered after prolonged administration of 100 nM
AL6 (data not shown).
To determine whether the increase in TSP-1 mRNA led to in-
creased TSP-1 secretion into the conditioned media, we analyzed
media from our samples by ELISA. We found that higher levels of
Figure 7. Cyclin D1 protein concentrations in cell lysates after exposure to C2, AL6, C6, and C8 or with vehicle alone for 144 hours in
(A) endothelial and (B) pancreatic cancer cell lines. (C) TSP-1 gene expression (2−ΔΔC t) in endothelial cell lines (HUVEC and HMVEC-d)
exposed to AL6 or to vehicle alone for 144 hours. (D) TSP-1 secretion in the conditioned media of HMVEC-d and HUVECs exposed to C2,
AL6, C6, and C8 or to vehicle alone for 144 hours. TSP-1 concentrations in conditioned media were measured by ELISA and normalized
to total protein concentration. Columns and bars, mean values ± SD, respectively. *P < .05 versus vehicle-treated controls.
Figure 6. (A) HUVEC control cells stained with hematoxylin (×20), (B) HUVEC vehicle-treated control (×20) positive for CAV-1 protein,
and (C) HUVEC treated with AL6, at 4 nM, for 144 hours (×20). Arrow points to positive immunoreactivity for CAV-1. The primary anti-
body dilution used was 1:200.
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TSP-1 were detectable in the conditioned media of drug-treated
endothelial cells (Figure 7D) compared with vehicle-treated controls.
In particular, a marked increase was found in HMVEC-d (227 ±
13% vs 100% of controls) treated with AL6 (5 nM) and a similar
result (180 ± 8% vs 100% of controls) was obtained with HUVECs
(Figure 7D).
In Vivo Studies
Metronomic C2 and AL6 inhibit tumor growth in vivo. In the
ceramide-treated groups (C2 and AL6, 0.5 mg/kg per day i.p.), the
tumor growths were markedly inhibited for more than 25 days after
the beginning of metronomic treatment. For example, after 27 days
of treatment, the average of C2-treated and AL6-treated tumors was
301 and 273 mm3 versus 860 mm3 of controls (corresponding to a
65% and a 68% inhibition), respectively. In the remaining 15 days,
these tumors relapsed. However, by the time the treatment was ter-
minated, the C2 and AL6 groups average tumor volumes were 717 and
988 mm3, respectively, compared to 1431 mm3 in the control group
(which corresponds to a percentage of growth inhibition of 50% for
C2 and 31% for AL6, compared to controls; Figure 8A). Similar anti-
tumor activity was observed in mice treated with MTD gemcitabine,
which we used as a positive control. For MTD gemcitabine, by the time
the treatment was terminated, the average tumor volume was 1125 mm3
(i.e., a 21% growth inhibition compared to controls; Figure 8A). All
compounds throughout the duration of the treatment did not cause
Figure 8. (A) Antitumor effect of 1) MTD gemcitabine, two cycles of 120 mg/kg four times at 3-day intervals i.p.; 2) metronomic ceramide
analog C2 everyday at 0.5 mg/kg per day i.p.; 3) metronomic ceramide analog AL6 everyday at 0.5 mg/kg per day i.p.; and 4) vehicle
alone [saline solution and 1.9% DMSO and 1.9% ethanol (vol/vol)] i.p. on MIA PaCa-2 cell tumor xenotransplanted in CD nu/nu mice.
(B) Body weight of MIA PaCa-2 tumor-bearing control mice and of mice treated with metronomic C2, AL6, and MTD gemcitabine sched-
ules. (C) Antitumor effect of 1) MTD gemcitabine, 2) metronomic ceramide analog C6, 3) metronomic ceramide analog C8, and 4) vehicle
alone. (D) Body weight of control mice and mice treated with metronomic C6, C8, and MTD gemcitabine schedules. Symbols and bars
indicate mean ± SEM. P < .05 versus vehicle-treated controls.
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any appreciable weight loss (Figure 8B). In contrast, despite the prom-
ising in vitro data we obtained, the metronomic C6 and C8 adminis-
tration (0.5 mg/kg per day i.p.) did not cause much tumor inhibition
in vivo compared to MTD gemcitabine (Figure 8C ). In this experi-
ment, C6 and C8 did not cause any significant weight loss (Figure 8D).
Metronomic C2 and AL6 significantly decrease microvessel density
and Ki67 staining in MIA PaCa-2 xenograft tumor. Histologic
staining with hematoxylin and eosin of subcutaneous MIA PaCa-2
cells was consistent with pancreatic adenocarcinoma (data not
shown). Well-defined CD31 immunoreactivity was found to be lo-
calized in endothelial cells inside the vehicle-alone–treated tumors
(Figure 9A). Microscopy analysis showed a clear reduction of micro-
vessels in the C2-treated and AL6-treated tumors (Figure 9, B and
C , respectively). Whereas control tumor xenografts showed a diffuse,
strong, and easily detectable immunoreactivity to Ki67 (Figure 9D),
a marked decrease in relative cell proliferation (i. e., a lower Ki67
staining) was observed in the C2-treated and AL6-treated tumors
compared to vehicle-treated controls (Figure 9, E and 9F , respec-
tively). In addition, compared to controls, metronomic C2 and
AL6 treatments resulted in a significant decrease in the microvessel
count and in the percentage of Ki67-positive cells after the quantifi-
cation of all available samples (Figure 9G ).
Discussion
MC has aroused a great deal of interest among investigators and
oncologists recently. That was possibly a direct consequence of
promising preclinical results and encouraging clinical data [3,5,7].
Moreover, the use of MC seems to eliminate or to greatly reduce
the usual toxic effects observed when chemotherapy is administered
at the MTD. This aspect increases patients’ compliance, thus improv-
ing their quality of life—a key element in the palliative treatment of
metastatic cancer such as that of the pancreas. This is of considerable
interest not only for the ongoing pancreatic cancer trials such as the
ones that include the testing of metronomic cyclophosphamide
(clinicaltrial.gov NCT00727441) but also for the planning of new
pancreas cancer metronomic treatments in the future. In this regard,
this tumor type has been clinically shown to have a significant inherent
resistance to chemotherapeutic drugs and to anti-VEGF treatments [1];
thus, a different therapeutic approach is urgently needed on the basis
Figure 9. Representative images of immunohistochemistry of mouse microvessel density in MIA PaCa-2 xenografts in (A) vehicle-treated
mice (control group) and (B) in metronomic C2-treated and (C) metronomic AL6-treated mice. Representative images of immunohisto-
chemistry of Ki67 in MIA PaCa-2 xenografts in (D) vehicle-treated mice (control group) and in (E) metronomic C2 and (F) metronomic AL6
groups of mice. Arrows point to positively stained cells. Original magnification, ×200. (G) Quantification of microvessel density and Ki67
immunostaining in MIA PaCa-2 tumor xenografts treated with vehicle alone, metronomic C2, or metronomic AL6, at the end of the in vivo
experiment. Columns and bars, mean values ± SD, respectively. *P < .05 versus vehicle-treated controls.
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of novel mechanism of actions. MC appears to act in part by the inhi-
bition of tumor neovascularization [6–8]. On this basis, we decided to
explore the possibility that not only the classic chemotherapeutic drugs
[7] but also other compounds such as ceramide analogs administered at
metronomic doses might have (similar) antitumor and antiangiogenic
effect in vitro and in vivo. Ceramide analogs have been investigated for
their antiproliferative and proapoptotic effects in human tumor cells,
including pancreatic tumor cells [30,35,44], showing interesting effects
but at high concentrations and at doses that unfortunately did not per-
mit their further clinical development. This study demonstrates, for the
first time, the antitumor and antiangiogenic effect of metronomic
ceramide analogs (C2, AL6, C6, and C8), both in vitro and in vivo.
This study highlights the possibility that these compounds (especially
C2 and AL6), when administered at nontoxic concentrations and for
prolonged periods of time, have preferential antiproliferative and pro-
apoptotic effects on activated endothelial cells. Thus, on the basis of our
data, we can define the in vitro metronomic ceramide analog schedule
as the frequent administration of low concentrations of ceramide ana-
logs that affect the proliferation of endothelial cells but not the prolif-
eration of cancer cells (approximately 5%, or less, of the administered
concentrations that determine, after 144 hours, the inhibition of 50%
of cancer cell proliferation). The effects of exogenous cell-permeable
short-chain ceramide analogs resulted in a striking decrease in endothe-
lial cell proliferation and increase of apoptosis. These events are likely
associated with perturbations in diverse cell signaling pathways, includ-
ing the inactivation of Akt through its dephosphorylation. The decrease
in pAkt has been described previously after the use of standard concen-
tration (e.g., micromolar) of ceramide analogs, such as C6, in cancer cells
[45]. Moreover, previous in vitro studies showed that sphingosine-1–
phosphate, a ceramide antagonist, protected endothelial cells in culture
from radiation-induced apoptosis [46] through the activation of the Akt
pathway [47]. On the basis of our data, the metronomic ceramide ana-
logs may induce apoptosis by two distinct mechanisms: 1) directly by
decreasing the cellular levels of pAkt and 2) by upregulating TSP-1.
With regard to the latter, TSP-1 up-regulation has been described
previously as a mediator of the effects of MC [7,48]. In addition, the
up-regulation of TSP-1 has been linked to the inhibition of Akt
phosphorylation as detailed in a study by Bussolati et al. [49], who re-
ported that the inhibition of Akt activation by phosphatidylinositol
3-kinase (PI3K) inhibitors is concomitant with the synthesis and the
release of TSP-1 by tumor endothelial cells, in agreement with a previous
report by Niu et al. [50]. In that study, loss of Akt signaling was found
to correlate with a gradual increase in TSP-1 levels in endothelial cells.
Indeed, TSP-1 has a direct impact on the remodeling of the vascular
endothelium, inducing caspase-dependent apoptosis through the
CD36 receptor. Moreover, TSP-1 is able to bind and sequestrate pro-
angiogenic growth factors and cytokines secreted by nonendothelial
cells, such as basic fibroblast growth factor and VEGF, thus reducing
endothelial cell survival, migration, and vascular sprouting [51]. Interest-
ingly, in our study, the secretion of TSP-1 protein was found increased
in the conditioned medium of ceramide analog–treated endothelial cells
versus vehicle-treated controls. However, the percentage of such increase
was similar, and not significantly different, between lower and higher
metronomic concentrations. This suggests a possible relevant role of
the proapoptotic effects of the increased TSP-1 in the lower doses rather
than at the higher ones, where inhibition of cell proliferation is more
relevant to the antiendothelial effects of metronomic ceramide analogs.
Our data suggests that the possible molecular mechanism for
inhibition of endothelial cell proliferation by metronomic ceramide
analogs is by a significant decrease of cyclin D1 and through the
inhibition of ERK1/2 phosphorylation. How do ceramide analogs
affect cyclin D1 expression? The data obtained seem to suggest that
the significant increase in the CAV-1 mRNA and protein expression,
after low-dose ceramide analog treatment, could play an important role
in the observed cyclin D1 down-regulation. Caveolin proteins serve as
the structural components of caveolae, while also functioning as scaf-
folding proteins, capable of recruiting numerous signaling molecules to
caveolae—as well as regulating their activity [52]. Moreover, it has
been demonstrated that CAV-1 can act as a tumor suppressor in the
mammary gland. In fact, CAV-1 is downregulated in the majority of
mammary tumor cell lines, and in these cell lines, recombinant re-
expression of CAV-1 potently inhibit their proliferation, their anchorage-
independent growth, and their invasiveness [53–55]. More importantly,
it has been shown that the loss of CAV-1 is associated with cyclin
D1 up-regulation and with ERK1/2 hyperactivation [56,57]. Thus,
Hulit et al. [58] showed that CAV-1 expression levels inversely cor-
related with cyclin D1 levels in cells. Expression of antisense CAV-1
increased cyclin D1 levels, whereas CAV-1 overexpression inhibited
the expression of cyclin D1 gene, suggesting that cyclin D1 promoter
activity is selectively repressed by CAV-1 [58]. These previously pub-
lished data are consistent with our findings, and we can therefore pro-
pose that metronomic ceramide analogs may inhibit endothelial cell
proliferation through this mechanism. However, it has been also shown
that ceramide can induce cell cycle arrest through the simultaneous
activation of stress-activating protein kinases and the inhibition of
ERK [59,60]. In that respect, ceramide seems to competitively inhibit
the ability of diacylglycerol-stimulated PKCɛ to disrupt the formation
of a Raf/MEK/ERK signalosome, an event that is also associated with
growth arrest [61].
In this study, we also sought to evaluate the antitumor and anti-
angiogenic activity of metronomic ceramide analogs in vivo. From
our previous experience [62] and from data of previously published
studies [34], we decided to treat animals with an MTD gemcitabine
regimen, as a positive control, and with the metronomic ceramide
analog schedules of 0.5 mg/kg per day. Our results show that metro-
nomic schedule of all four compounds was very well tolerated when
compared with the gemcitabine MTD regimen. Indeed, no signifi-
cant animal weight loss was observed compared to the control group,
which is consistent with our previously published results with MC in
gastrointestinal tumor models [39,63,64]. Another major finding of
our in vivo experiments was the demonstration of both antitumor
and antiangiogenic activities of the metronomic administered C2 and
AL6 compounds in subcutaneously implanted pancreatic tumors.
Indeed, these ceramide analogs significantly delay tumor growth with
kinetics that is consistent with the inhibitory effect seen with gemcita-
bine MTD treatment. Moreover, both microvessel density and pro-
liferation rate were markedly decreased in tumors treated with
metronomic C2 and AL6 schedules when compared to control group,
a result consistent with our in vitro data. Interestingly, not all ceramide
analogs tested in this study showed a significant in vivo effect in tumor
xenografts. The C6 and C8 compounds did not show any significant
activity in vivo, although they were administered at the same doses and
with the same schedules as the other drugs. This is in spite of the fact
that they showed similar in vitro data to that seen with the C2 and AL6
compounds. These data seem to suggest different pharmacokinetic
characteristics of C6 and C8 analogs (e.g., tissue distribution), probably
because of their different chemical structures rather than different
pharmacodynamic properties. Unfortunately, to our knowledge, for
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short-chain cell-permeable ceramide analogs (such as C2, C6, and C8),
there are no described in vivo pharmacokinetic studies. However,
Stover and Kester [65] have described the 3[H]-C6 in vitro kinetics
in breast cancer cells. The ceramide analog C6 reached the maximum
intracellular concentration after 6 to 8 hours from the start of treatment
and maintained measurable intracellular concentrations for almost
another 10 hours. Future pharmacokinetic studies will probably be
necessary to rationally explain the differences in antitumor efficacy that
we observed.
In conclusion, metronomic ceramide analogs show significant
antitumor and antiangiogenic activity in the absence of significant
toxicity. These data could renew interest in translational cancer re-
search using this class of compounds. Indeed, the potential benefit
of ceramide-based MC in cancer is based on the ability of exogenous
short-chain ceramide analogs to induce apoptosis and inhibition of
proliferation/migration in endothelial cells. In that regard, exogenous
ceramide analogs may synergistically augment the antiangiogenic and
antitumor activity of other MC schedules. For example, low-dose
metronomic oral dosing of LY2334737 [66], a prodrug of gemcitabine,
was recently shown to have antitumor activity with a concomitant in-
crease in intratumoral blood flow, an effect that may be of benefit for
the delivery of drugs to tumors such as pancreatic cancer. Furthermore,
one already reported effective combination is that of ceramide analogs
plus paclitaxel. Thus, paclitaxel induction of apoptosis was found to be
synergistically enhanced by C6 ceramide analog in nanoemulsion for-
mulations [67]. Moreover, the identification of endothelial cell as a tar-
get population of ceramide analogs should allow the design of even
more specific or potent ceramide analogs, or mimetics, for cancer ther-
apy. For example, the potential to incorporate short-chain ceramide
analogs into conventional or cationic liposomal delivery systems may
not only improve efficiency of transfer but also may serve to augment
the antiangiogenic effects of these compounds.
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Figure W1. Representative microscopic picture of migrated endo-
thelial cells in an 8-μm pore modified Boyden chamber. After 4
hours of drug treatments, the membranes were fixed, stained with
hematoxylin, and then mounted onto slides. The pictures of the
migrated cells were acquired using a digital microscope and pro-
cessed by image analysis software. The migrated cells were
counted by a software command (small yellow numbers). Arrow-
heads, pores occupied by migrated endothelial cells; arrows, mi-
grated cells.
